Results 151 to 160 of about 211,431 (346)

Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE‐522 Japan Subgroup Analysis

Cancer Science, EarlyView.
In the global, phase 3 KEYNOTE‐522 study of high‐risk early‐stage triple‐negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved efficacy outcomes versus neoadjuvant chemotherapy alone. In this analysis of Japanese participants from KEYNOTE‐522, neoadjuvant pembrolizumab plus chemotherapy ...
Masato Takahashi, Hirofumi Mukai, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Mitsuya Itoh, Junichiro Watanabe, Yuko Tanabe, Naohito Yamamoto, Yasuo Miyoshi, Kenichi Watanabe, Toru Mukohara, Yibin Kong, Masashi Shimura, Francisco Beca, Peter Schmid, Hiroji Iwata   +16 more
wiley   +1 more source

Use of qSOFA criteria in prediction of poor prognosis in acute pancreatitis

, 2019
Mehmet Cagri Goktekın
openalex   +2 more sources

S07 * COMBINED DEPENDENCE FROM ALCOHOL AND TOBACCO: INTERACTIONS AND CLINICAL IMPLICATIONS * S07.1 * THE IMPACT OF SMOKING AND ALCOHOL ON ACUTE AND CHRONIC PANCREATITIS IN THE WESTERN WORLD [PDF]

, 2011
R. Pfützer, Norbert Wodarz, Fredrick Weber, A. Grundl, S. Appel, Monika Ridinger, Sebastian Müller, Sylvie Petitjean, Bigna Degen, Gerhard A. Wiesbeck, Stephan Haas   +10 more
openalex   +1 more source

MINIMALLY INVASIVE TECHNIQUES TO TREAT THE COMPLICATIONS OF ACUTE PANCREATITIS

, 2023
VYACHESLAV F. CHIKAEV
openalex   +1 more source

A Rare Case of Thrombotic Thrombocytopenic Purpura Caused by Acute Pancreatitis [PDF]

, 2021
Emin Gemcioğlu, M. Levent Kayaalp, Merve Caglayan, Ahmet Cevdet Ceylan, Mehmet Sezgin Pepeler   +4 more
openalex   +1 more source

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

Cancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto   +14 more
wiley   +1 more source

Late outcome after pylorus preserving pancreaticoduodenectomy for ampullary carcinoma following severe acute post-stenting pancreatitis: and review of the literature [PDF]

, 2011
Magdalena Skórzewska, Wojciech Polkowski   +1 more
openalex   +1 more source

Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches

Developing World Bioethics, EarlyView.
ABSTRACT This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create ‘valleys of death’ that prevent innovation from reaching ...
Ubaka Ogbogu, Lauren Albrecht
wiley   +1 more source

Pathogenesis and Therapy of Coagulation Disorders in Severe Acute Pancreatitis

, 2023
Menglu Gui, Bing Zhao, Jun Huang, Erzhen Chen, Hongping Qu, Enqiang Mao   +5 more
openalex   +2 more sources

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source